US 12,433,914 B2
Methods of administering safe colon cleansing compositions
Edmund V. Dennett, Walpole, MA (US); Mark Cleveland, Norwell, MA (US); Russell W. Pelham, Duxbury, MA (US); and Matthew Walker, Brighton, MA (US)
Assigned to Braintree Laboratories, Inc., Braintree, MA (US)
Filed by Braintree Laboratories, Inc., Braintree, MA (US)
Filed on Feb. 25, 2025, as Appl. No. 19/062,757.
Application 19/062,757 is a continuation of application No. 18/792,849, filed on Aug. 2, 2024, granted, now 12,290,529.
Application 18/792,849 is a continuation of application No. 18/743,526, filed on Jun. 14, 2024, granted, now 12,239,659.
Claims priority of provisional application 63/521,314, filed on Jun. 15, 2023.
Prior Publication US 2025/0186484 A1, Jun. 12, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/765 (2006.01); A61K 9/08 (2006.01); A61K 33/04 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61P 1/10 (2006.01)
CPC A61K 31/765 (2013.01) [A61K 9/08 (2013.01); A61K 33/04 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61P 1/10 (2018.01)] 11 Claims
 
1. A method of cleansing a colon of a patient, the method comprising:
(a) administering to the patient a first dose of a colon cleansing product comprising about 178.7 grams of polyethylene glycol, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, about 0.5 grams of sodium chloride, malic acid, and citric acid mixed in about 0.5 liters to about 1.0 liters of water;
(b) administering to the patient a second dose of the colon cleansing product comprising about 178.7 grams of polyethylene glycol, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, about 0.5 grams of sodium chloride, malic acid, and citric acid mixed in about 0.5 liters to about 1.0 liters of water; and
wherein consumption of the first dose and second dose cleanses the colon of the patient sufficiently for diagnostic and surgical procedures to be performed, and wherein the combination of the first dose and the second dose does not cause a sodium balance of −50.00 mEq/L or greater in the patient.